MentionFox
Home › funding signals › Kamal Therapeutics, Inc.
Form D · on the record

Kamal Therapeutics — $13.81M Form D filing, November 2025

Kamal Therapeutics, Inc. filed a Form D with the Securities and Exchange Commission on 2025-11-24.

Kamal Therapeutics, Inc. filed a Form D notice of an exempt securities offering with the SEC on November 24, 2025. The filing reports $13.81M sold. Its industry group is Pharmaceuticals. It names Mark de Souza (Executive Officer, Director), Philip Reilly (Director), John Parker (Director) (SEC Form D, November 24, 2025).

Sell to companies like Kamal Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Opens in a new tab. No signup.

88 companies raised this week, 1 had other signals.

Companies that just raised money, and the people to call. Before you unlock: the company, the amount, the date and what is inside (for example 2 people, phone, LinkedIn). After: the officers and directors the filing names with their roles, how to reach the company, and a person's email only when we found one.

fal - Features & Labels, Inc.$1BAI and software
fal - Features & Labels, Inc.$350MAI and software
SIERRA INTERNATIONAL NETWORK INC$300MAI and software
Zai Lab Ltd$250MBiotech
Databento Inc.$100MAI and software
Check one company free All companies that raised this week

5 more Pharmaceuticals raises in Massachusetts within 90 days ↓

Is this your company?

Key facts

Run the free check on Kamal Therapeutics, Inc. →

Kamal Therapeutics, Inc.

New Form D on file · 2025-11-24 · the record

$13.81M
raise on the record
D
filing
41
investors in
MASSACHUSETTS
based
Open the record →

What the record says

FilingForm D
Filed2025-11-24
Industry groupPharmaceuticals
Entity typeCorporation
Incorporated inDELAWARE
Year formed2020
BasedHINGHAM, MASSACHUSETTS
CIK1880064
Accession0001880064-25-000004

Pitching, partnering or investing alongside them? See who really runs and owns Kamal Therapeutics, Inc.

Free to see. No signup.

Keep reading

More on the people and the money behind Kamal Therapeutics, Inc., from the filings we hold.

More raises like this

Pharmaceuticals raises by companies based in Massachusetts, filed within 90 days of this one, largest first.

What do you want to do with Kamal Therapeutics, Inc.?

Get the full cited report on Kamal Therapeutics, Inc.

What the filing shows about Kamal Therapeutics, Inc.

  • 41 investors had already put money in when it filed.
  • The filing names 3 people as officers, directors or promoters.

Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.

Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News

A Full Report on Kamal Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

See a sample report

Just raised? Your investors will ask for updates.

The weeks after a raise are when investors, other founders and press look Kamal Therapeutics, Inc. up. FoxPlug is your startup's chief of staff: it reads your whole stack and tells you what to fix, what to say and what to skip, for founders shipping with Claude Code, Codex or Cursor. It drafts your monthly investor update from your real numbers, and its free tools need no account. GetFoxChat puts an AI operator on Kamal Therapeutics, Inc.'s own site, named as you like, so the visitors this record sends you don't read one page and leave.

Who the filing names, and in what role

The filing gives Kamal Therapeutics, Inc.'s address as 66 Clubhouse Drive, Hingham, MA 02043.

What the filing says

  • Offered: $17,307,138. Sold: $13,807,138. Left to sell: $3,500,000. (filing)
  • Investors: 41 had already invested. (filing)
  • Date of first sale: November 10, 2025. (filing)
  • Types of securities: Equity. (filing)
  • Item 16: the filing reports that none of the proceeds goes to executive officers, directors or promoters. (filing)

This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.

Order the Full Report on Kamal Therapeutics, Inc. See pricing

Is Kamal Therapeutics, Inc. a real, registered company?

Kamal Therapeutics, Inc. is a registered filer with the SEC (CIK 1880064) and has filed since 2025-11-24. 1 filing is on record, the latest on 2025-11-24.

A filing shows the company exists and what it reports about itself. It is not an audit or a rating.

Who runs Kamal Therapeutics, Inc.?

Kamal Therapeutics, Inc.'s Form D of 2025-11-24 names Mark de Souza, Philip Reilly and John Parker as its officers, directors or promoters.

How much has Kamal Therapeutics, Inc. raised?

Its new offerings report $13.81M sold across 1 offering, as its own filings state.

Filing history · 2 filings on this registrant
Form D/A, amended · 2022-10-11 · $9.94MForm D · 2025-11-24 · $13.81M · this page 2022-10-11 2025-11-24

A hollow marker is an amendment (Form D/A); a solid one is an original Form D. The larger marker is the filing this page is about.

Pharmaceuticals · by week
This raise, $13.81M, filed week of Nov 24

Trailing twelve months. 155 filings in Pharmaceuticals, totalled by week. The dot is this raise, $13.81M, on the same scale — one filing against the whole group's total, so it sits low by construction.

Want the whole picture on Kamal Therapeutics, Inc.?

What the filing shows about Kamal Therapeutics, Inc.

  • 41 investors had already put money in when it filed.
  • The filing names 3 people as officers, directors or promoters.

Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.

Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News

A Full Report on Kamal Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Kamal Therapeutics, Inc. covers

  1. The Short Answer

  2. Which Company This Is

  3. What They Do, And How The Money Works

  4. Who Runs It, And How To Reach Them

  5. The Money: Funding, Valuation, Runway

  6. Who Pays Them, And Who They Are Up Against

  7. Warning Bells

  8. Sources

    1 cited source found

Plus the sections for what you are deciding, which you pick after ordering.

See a sample report

First screen of a real sample Full Report on EchoStar: the verdict, 17 sections, 63 cited sources, built 2026-10-21A real finished report, first screen. Opens in a new tab.

The full profile

Checking your access…

Sourced from the filing index on sec.gov.

Follow this companyRSS

Tools for this story

Each opens in a new tab, filled in for Kamal Therapeutics, Inc.. With no account yet, you sign up free and land on the result.

Share this page

Is this your company?

Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.

Kamal Therapeutics, Inc.: Raised $13.81M, Form D filed 2025-11-24
Share on LinkedIn Share on X Download image

Cite this page

Permanent URL: https://mentionfox.com/funding/kamal-therapeutics-inc-form-d-25000001
Last updated 2026-10-29
Primary record: SEC filing 1 · SEC filing 2
Kamal Therapeutics raised $13.81M — SEC Form D filing, November 2025. MentionFox, 2026-10-29. https://mentionfox.com/funding/kamal-therapeutics-inc-form-d-25000001